The estimated Net Worth of Frances Arnold is at least $4.35 Миллион dollars as of 30 April 2024. Frances Arnold owns over 80 units of Illumina Inc stock worth over $1,941,231 and over the last 9 years he sold ILMN stock worth over $1,923,887. In addition, he makes $481,850 as Independent Director at Illumina Inc.
Sign up
Frances Arnold ILMN stock SEC Form 4 insiders trading
Frances has made over 20 trades of the Illumina Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 80 units of ILMN stock worth $13,390 on 30 April 2024.
The largest trade he's ever made was selling 1,503 units of Illumina Inc stock on 11 May 2020 worth over $464,592. On average, Frances trades about 236 units every 67 days since 2016. As of 30 April 2024 he still owns at least 15,551 units of Illumina Inc stock.
You can see the complete history of Frances Arnold stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Frances Arnold biography
Dr. Frances Arnold, Ph.D. is an Independent Director of Illumina, Inc. Dr. Arnold manages a research group at the California Institute of Technology and is the Dick and Barbara Dickinson Professor of Chemical Engineering, Bioengineering and Biochemistry at the California Institute of Technology and Director of the Donna and Benjamin M. Rosen Bioengineering Center. She joined the California Institute of Technology in 1986 and has served as a Visiting Associate, Assistant Professor, Professor, and Director. Dr. Arnold’s laboratory focuses on protein engineering by directed evolution, with applications in alternative energy, chemicals, and medicine. She is the recipient of numerous honors, including induction into the National Inventors Hall of Fame, Fellow of the National Academy of Inventors, the ENI Prize in Renewable and Nonconventional Energy, the U.S. National Medal of Technology and Innovation, and the Charles Stark Draper Prize of the U.S. National Academy of Engineering. Dr. Arnold is an elected member of all three U.S. National Academics of Science, Medicine, and Engineering, as well as the American Academy of Arts and Sciences. Dr. Arnold received a B.S. in mechanical and aerospace engineering from Princeton University and a Ph.D. in chemical engineering from the University of California, Berkeley.
What is the salary of Frances Arnold?
As the Independent Director of Illumina Inc, the total compensation of Frances Arnold at Illumina Inc is $481,850. There are 16 executives at Illumina Inc getting paid more, with Mostafa Ronaghi having the highest compensation of $3,541,310.
How old is Frances Arnold?
Frances Arnold is 63, he's been the Independent Director of Illumina Inc since 2016. There are 3 older and 19 younger executives at Illumina Inc. The oldest executive at Illumina Inc is John Thompson, 71, who is the Lead Independent Director.
What's Frances Arnold's mailing address?
Frances's mailing address filed with the SEC is C/O ALPHABET INC., 1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW, CA, 94043.
Insiders trading at Illumina Inc
Over the last 21 years, insiders at Illumina Inc have traded over $412,190,379 worth of Illumina Inc stock and bought 13,386 units worth $1,243,499 . The most active insiders traders include John Wendell Thompson, Jay T Flatley и Robert Nelsen. On average, Illumina Inc executives and independent directors trade stock every 5 days with the average trade being worth of $954,700. The most recent stock trade was executed by Jacob Thaysen on 22 February 2024, trading 7,330 units of ILMN stock currently worth $991,676.
What does Illumina Inc do?
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
What does Illumina Inc's logo look like?
Complete history of Frances Arnold stock trades at Alphabet Inc, Alphabet Inc и Illumina Inc
Illumina Inc executives and stock owners
Illumina Inc executives and other stock owners filed with the SEC include:
-
Mostafa Ronaghi,
Senior Vice President of Entrepreneurial Development -
Mark Van Oene,
Senior Vice President, Chief Commercial Officer -
Jay Flatley,
Executive Chairman of the Board -
Joydeep Goswami,
Senior Vice President - Corporate Development and Strategic Planning -
Charles Dadswell,
Senior Vice President, General Counsel, Secretary -
Francis deSouza,
President, Chief Executive Officer, Director -
Susan Siegel,
Independent Director -
Dr. Alexander Aravanis M.D., Ph.D.,
CTO & Head of Research and Product Devel. -
Aimee Hoyt,
Senior Vice President and Chief People Officer -
Sam A. Samad,
Chief Financial Officer -
Susan H. Tousi,
Chief Commercial Officer -
Sam Samad,
Chief Financial Officer, Senior Vice President -
Caroline Dorsa,
Independent Director -
John Thompson,
Lead Independent Director -
Robert Epstein,
Independent Director -
Gary Guthart,
Independent Director -
Frances Arnold,
Independent Director -
Philip Schiller,
Independent Director -
Jacquie Ross,
Vice President, Investor Relations -
Scott Gottlieb,
Independent Director -
Alex Aravanis,
Chief Technology Officer -
Phillip Febbo,
Senior Vice President, Chief Medical Officer -
Carissa Rollins,
Chief Information Officer -
Sallilyn Schwartz,
VP of Investor Relations -
Kevin Carl Pegels,
Chief of Global Operations -
Francis A. deSouza,
CEO & Director -
Charles E. Dadswell,
Sr. VP, Gen. Counsel & Sec. -
Juliet Cunningham,
VP of Investor Relations -
Steve Phillpott,
Sr. VP & Chief Information Officer -
Jose A. Torres Jr.,
Chief Accounting Officer & VP -
Robert P. Ragusa,
Chief Operations Officer -
Stephanie Campos,
Pres -
Kathryne Gambrell Reeves,
SVP, Chief Marketing Officer -
Daniel Bradbury,
Director -
A Blaine Bowman,
Director -
Omead Ostadan,
SVP Mktg, Prod & Strat Plan -
Karin Eastham,
Director -
Patricia Leckman,
SVP, Chief People Officer -
Malcolm Garret Hampton,
SVP Clinical Genomics Group -
Karen K Mcginnis,
VP, Chief Accounting Officer -
Jacob Thaysen,
Chief Executive Officer -
Robert P Ragusa,
SVP, Global Quality & Ops -
Susan H Tousi,
SVP, Chief Commercial Officer -
David R Walt,
Director -
William H Rastetter,
Director -
Nicholas Naclerio,
Sr VP, Corporate & Venture Dev -
Tristan Orpin,
VP Worldwide Sales -
Richard Klausner,
Sr VP, Chief Medical Officer -
Roy A Whitfield,
Director -
Jeff Huber,
Director -
Marc Stapley,
Sr VP & CFO -
Gerald Moeller,
Director -
Paul L Bianchi,
Sr VP, Human Resources -
Michel Bouchard,
Chief Accounting Officer -
Mark L Lewis,
Sr VP & GM Molecular Biology -
Gregory Heath,
Sr. VP and GM, Diagnostics -
Matthew L. Posard,
Sr VP & GM, Consumer Genomics -
Christian O Henry,
CFO, VP Finance -
Paul C Grint,
Director -
Christian Cabou,
Sr. VP and General Counsel -
Jack Goldstein,
Director -
Joel Mc Comb,
Sr. VP and GM, Life Sciences -
Stephen P Macmillan,
Director -
Alan Kersey,
V.P. & Site Manager -
John R Stuelpnagel,
VP Business Development -
John West,
Sr VP & GM DNA Sequencing -
David C Douglas,
Vice President Manufacturing -
Scott D Kahn,
Chief Information Officer -
Paulette D Cabral,
Vice President Human Resources -
Timothy M Kish,
VP Finance & CFO -
Arnold R Oliphant,
VP Scientific Operations -
R Scott Greer,
Director -
Arthur Holden,
Sr. VP Corp and Market Dev -
David L Barker,
Chief Scientific Officer -
Ventures Iii Lp Cw,
10% owner -
Clinton Bybee,
10% owner -
Keith Crandell,
10% owner -
Kirk Malloy,
V.P. of Customer Solutions -
George Poste,
Director -
Robert Nelsen,
Director -
Noemi C Espinosa,
VP Intellectual Property -
Robert C Kain,
Vice President Engineering -
Steven Lazarus,
10% owner -
Venture Fund Iii L P Arch,
10% owner -
Venture Partners Llc Arch,
10% owner -
Christensen Jakob Wedel,
SVP, Strategy/Corp Development -
Ankur Dhingra,
SVP, Chief Financial Officer -
Anna Richo,
Director -
Jose Torres,
VP, Chief Accounting Officer -
Kevin Carl Pegels,
Chief of Global Operations -
Scott B. Ullem,
Director -
Carissa Rollins,
SVP, Chief Information Officer -
John Edward Frank,
Chief Public Affairs Officer -
Steven Barnard,
SVP, Chief Technology Officer -
Scott D Ericksen,
VP, Chief Accounting Officer -
Everett Cunningham,
SVP, Chief Commercial Officer